Cantel Medical Corp. (NYSE:CMN) Chairman Charles M. Diker sold 14,897 shares of the company’s stock in a transaction dated Monday, October 10th. The shares were sold at an average price of $78.76, for a total value of $1,173,287.72. Following the completion of the transaction, the chairman now owns 3,190,111 shares in the company, valued at approximately $251,253,142.36. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
Cantel Medical Corp. (NYSE:CMN) opened at 75.56 on Monday. The company has a 50-day moving average price of $77.84 and a 200-day moving average price of $71.26. Cantel Medical Corp. has a 12-month low of $55.01 and a 12-month high of $81.63. The firm has a market cap of $3.13 billion, a P/E ratio of 52.55 and a beta of 1.59.
Cantel Medical Corp. (NYSE:CMN) last posted its quarterly earnings results on Thursday, September 29th. The company reported $0.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.11. The business had revenue of $179 million for the quarter. Cantel Medical Corp. had a return on equity of 16.70% and a net margin of 9.02%. Cantel Medical Corp.’s revenue was up 18.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.39 EPS. On average, analysts predict that Cantel Medical Corp. will post $1.98 earnings per share for the current year.
CMN has been the topic of a number of research reports. Needham & Company LLC initiated coverage on Cantel Medical Corp. in a report on Wednesday, August 24th. They issued a “hold” rating on the stock. Benchmark Co. initiated coverage on Cantel Medical Corp. in a report on Monday, August 29th. They issued a “buy” rating and a $83.00 target price on the stock.
A number of institutional investors have recently bought and sold shares of the stock. State Street Corp boosted its position in Cantel Medical Corp. by 1.4% in the first quarter. State Street Corp now owns 698,437 shares of the company’s stock valued at $49,838,000 after buying an additional 9,417 shares in the last quarter. UBS Group AG boosted its position in Cantel Medical Corp. by 2.6% in the first quarter. UBS Group AG now owns 52,630 shares of the company’s stock valued at $3,756,000 after buying an additional 1,348 shares in the last quarter. BlackRock Group LTD boosted its position in Cantel Medical Corp. by 9.5% in the first quarter. BlackRock Group LTD now owns 42,830 shares of the company’s stock valued at $3,056,000 after buying an additional 3,701 shares in the last quarter. Bogle Investment Management L P DE purchased a new position in Cantel Medical Corp. during the first quarter valued at about $228,000. Finally, Advisors Asset Management Inc. purchased a new position in Cantel Medical Corp. during the second quarter valued at about $6,672,000. Institutional investors and hedge funds own 81.61% of the company’s stock.
About Cantel Medical Corp.
Cantel Medical Corp. is a provider of infection prevention and control products and services in the healthcare market. The Company’s segments include Endoscopy, Water Purification and Filtration, Healthcare Disposables, Dialysis and Specialty Packaging. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies.
Receive News & Ratings for Cantel Medical Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical Corp. and related companies with MarketBeat.com's FREE daily email newsletter.